Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 507789 | NSE: JAGSNPHARM | Pharmaceuticals & Drugs | Small Cap

Jagsonpal Pharma Share Price

207.20 -10.95 -5.02%
as on 05-Dec'25 14:30

Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 507789 | NSE: JAGSNPHARM | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Jagsonpal Pharma

Based on:

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Jagsonpal Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
23.52
Market Cap:
1,456.8 Cr.
52-wk low:
194
52-wk high:
301.8

Is Jagsonpal Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Jagsonpal Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jagsonpal Pharmaceuticals Ltd is a good quality company.

2. Is Jagsonpal Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Jagsonpal Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Jagsonpal Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Jagsonpal Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Jagsonpal Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jagsonpal Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 7.3%14.3%-10.5%9.8%9.5%19.4%21.2%24.2%17.7%33.1%-
Value Creation
Index
-0.50.0-1.8-0.3-0.30.40.50.70.31.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 143144127167159188218237209269283
Sales YoY Gr.-0.3%-12.1%31.9%-5%18.5%15.8%8.8%-11.8%28.8%-
Adj EPS 0.50.4-1.81.11.22.62.84.13.46.39.3
YoY Gr.--12%-500%NA9.1%116.7%7.7%46.4%-17.1%84.1%-
BVPS (₹) 13.815.613.814.815.817.420.322.925.832.837.9
Adj Net
Profit
3.32.9-11.67.27.917.118.426.822.541.662
Cash Flow from Ops. 9-3.2-1.630.911.928.26.946.735.255.3-
Debt/CF from Ops. 4.3-2.5-5.30.10.50.20000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 7.2%11.1%7.3%28.8%
Adj EPS 32.4%39.2%30.8%84.1%
BVPS10.1%15.8%17.4%27.4%
Share Price 26% 53.7% 15.6% -26.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
3.42.8-11.17.17.314.614.418.41319.526.3
Op. Profit
Mgn %
8.24-8.85.65.410.211.714.611.11919.5
Net Profit
Mgn %
2.32-9.14.359.18.411.310.815.521.9
Debt to
Equity
0.40.10.100.10.100000
Working Cap
Days
227243277178164130102969277123
Cash Conv.
Cycle
180190209110855526262720103

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 26.30%

Net Profit is growing at healthy rate in last 3 years 30.76%

Sales growth is good in last 4 quarters at 28.54%

Sales growth has been subdued in last 3 years 7.29%

Latest Financials - Jagsonpal Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 9.3 -
TTM Sales (₹ Cr.) 283 -
BVPS (₹.) 37.9 -
Reserves (₹ Cr.) 240 -
P/BV 5.76 -
PE 23.52 -
From the Market
52 Week Low / High (₹) 194.00 / 301.80
All Time Low / High (₹) 0.50 / 328.02
Market Cap (₹ Cr.) 1,457
Equity (₹ Cr.) 13.4
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Jagsonpal Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Jagsonpal Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Jagsonpal Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales143144127167159188218237209269
Operating Expenses 132138138157150169193203186218
Manufacturing Costs4322112111
Material Costs59596173568189928096
Employee Cost 38414247505458656271
Other Costs 31353336423344444349
Operating Profit 126-11991925342351
Operating Profit Margin (%) 8.2%4.0%-8.8%5.6%5.4%10.2%11.5%14.4%11.1%19.0%
Other Income 1001343698
Interest 5311110011
Depreciation 3201112128
Exceptional Items 01300000-3020
Profit Before Tax 414-12992227353070
Tax 13-022588714
Profit After Tax 312-12781719272255
PAT Margin (%) 2.3%8.2%-9.1%4.3%5.0%9.1%8.7%11.3%10.8%20.6%
Adjusted EPS (₹)0.51.8-1.81.11.22.62.94.13.48.3
Dividend Payout Ratio (%)8%2%-2%9%17%15%56%49%59%30%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 9811098104111122133150170218
Share Capital 13131313131313131313
Reserves 8597859198109120137157205
Minority Interest0000000000
Debt38884670000
Long Term Debt0000000000
Short Term Debt38884670000
Trade Payables10991212181917810
Others Liabilities 13161416201720364764
Total Liabilities 159143130136149164171203225292

Fixed Assets

Gross Block905354555860583312103
Accumulated Depreciation39313233343436929
Net Fixed Assets 5222212224262324994
CWIP 0034200000
Investments 0000111551100
Inventories40485133293030211515
Trade Receivables42392521211316211113
Cash Equivalents flag 16201539406025115148129
Others Assets 11141418202128214140
Total Assets 159143130136149164171203225292

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 9-3-23112287473555
PBT 414-12992227353070
Adjustment 8-910-1-2-1108-12
Changes in Working Capital -2-6920512-11966
Tax Paid -1-302-2-3-7-7-9-8
Cash Flow From Investing Activity -241-3-1-11-2-26-58-25-45
Capex -341-4-2-2-0-01-035
Net Investments 0000-11-4-27-62-325
Others 100122237-86
Cash Flow From Financing Activity -6-34-1-6-2-7-18-0-9-12
Net Proceeds from Shares 00000-40063
Net Proceeds from Borrowing 000000-7000
Interest Paid -5-3-1-1-1-1-0-0-1-1
Dividend Paid -0-0-0-1-1-3-100-13-13
Others -1-310-500-0-0-1-1
Net Cash Flow 15-624-119-36-112-2

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)3.6512.32-12.017.727.8815.715.2818.8914.0228.51
ROCE (%)7.3214.26-10.529.89.4619.4321.2324.1517.7233.14
Asset Turnover Ratio0.920.960.931.261.111.21.451.381.051.09
PAT to CFO Conversion(x)3-0.25N/A4.431.51.650.371.741.591
Working Capital Days
Receivable Days1101029350493321262616
Inventory Days9211014392715745362920
Payable Days43495452776775695533

Jagsonpal Pharmaceuticals Ltd Stock News

Jagsonpal Pharmaceuticals Ltd FAQs

The current trading price of Jagsonpal Pharma on 05-Dec-2025 14:30 is ₹207.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Jagsonpal Pharma stood at ₹1,456.8.
The latest P/E ratio of Jagsonpal Pharma as of 04-Dec-2025 is 23.52.
The latest P/B ratio of Jagsonpal Pharma as of 04-Dec-2025 is 5.76.
The 52-week high of Jagsonpal Pharma is ₹301.8 and the 52-week low is ₹194.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jagsonpal Pharma is ₹282.7 ( Cr.) .

About Jagsonpal Pharmaceuticals Ltd

In 1964 Jagsonpal started from humble beginnings with Jagmohan S. Kochhar operating a chemists shop in Delhi. Soon he expanded into making formulations. Mr. Kochhar’s vision was to spread health and healing in India on a larger scale. He was at the helm of the company from its inception, through the startup phase. Even though Jagsonpal was a small business at the time, his vision was to create one of India’s premiere pharmaceutical companies.

In 1978, Fourteen years later, the company had outgrown the startup phase and was incorporated as a private limited company. Jagsonpal was now a fast growing pharmaceutical company. The firm was committed to healing India with quality pharmaceutical products and had its eyes firmly set on becoming one of the country’s leading pharmaceutical companies.

In 1986 Jagsonpal went public on the BSE. This was the first time the firm had tapped the capital markets.

In 1994 the company was listed on the NSE. This trait of not being content with the status quo has become a core part of Jagsonpal’s company culture. Commitment to growth is ingrained in the very soul of the company and this is reflected in the Jagsonpal’s current aggressive growth strategy.

Jagsonpal is among India’s premiere pharmaceutical companies. Jagsonpal has substantial research and development, manufacturing, marketing and distribution facilities. An impeccable track record of growth and profitability spanning over 4 decades, makes Jagsonpal an ideal company to partner with. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. The firm is committed to sustainable growth and is aggressively pursuing growth through market penetration, market expansion and multi-national expansion.

The firm’s objective is to increase market share and become a dominant player in the Indian Pharmaceutical Industry.Jagsonpal has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation.

Product range of the company includes:

  • Dextropropoxyphene
  • Tolnaftate 
  • Indocap SR
  •  Sterile Unipacks 
  • Thiopental sodium

Upcoming products:

  • Nandralone laurate
  • Ethisterone
  • Norgestimate
  • Estradiol
  • Estradiol benzoate
  • Estradiol valerate
  • Estradiol phenylpropionate
  • Mifepristone
  • Finasteride/dutasteride
  • Budesonide
  • Cyproterone/acetate
  • Mestranol
  • Llynestrenol
  • Norethisterone enanthate
  • Estriol base and succinate
  • Ethinyl estradiol
  • Estrone
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×